{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:56:49Z","timestamp":1687784209270},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00115-022-01287-1","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T14:02:44Z","timestamp":1649253764000},"page":"537-548","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prinzipien der translationalen Gentherapie f\u00fcr neuromuskul\u00e4re Erkrankungen"],"prefix":"10.1007","volume":"93","author":[{"given":"B.","family":"Schoser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"1287_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","volume":"100","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy\u00a0SA, Mendell\u00a0JR (2019) From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatr Neurol 100:3\u201311","journal-title":"Pediatr Neurol"},{"key":"1287_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3233\/JND-200560","volume":"8","author":"Y Aoki","year":"2021","unstructured":"Aoki\u00a0Y, Wood\u00a0MJA (2021) Emerging oligonucleotide therapeutics for rare neuromuscular diseases. J\u00a0Neuromuscul Dis 8:869\u2013884","journal-title":"J Neuromuscul Dis"},{"key":"1287_CR3","doi-asserted-by":"publisher","first-page":"e0212198","DOI":"10.1371\/journal.pone.0212198","volume":"14","author":"H Baba\u010di\u0107","year":"2019","unstructured":"Baba\u010di\u0107\u00a0H, Mehta\u00a0A, Merkel\u00a0O, Schoser\u00a0B (2019) CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: a systematic review. PLoS ONE 14:e212198","journal-title":"PLoS ONE"},{"key":"1287_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2131\/jts.46.57","volume":"46","author":"MW Bolt","year":"2021","unstructured":"Bolt\u00a0MW, Brady\u00a0JT, Whiteley\u00a0LO, Khan\u00a0KN (2021) Development challenges associated with rAAV-based gene therapies. J\u00a0Toxicol Sci 46:57\u201368","journal-title":"J Toxicol Sci"},{"key":"1287_CR5","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1172\/JCI136873","volume":"130","author":"F Chemello","year":"2020","unstructured":"Chemello\u00a0F, Bassel-Duby\u00a0R, Olson\u00a0EN (2020) Correction of muscular dystrophies by CRISPR gene editing. J\u00a0Clin Invest 130:2766\u20132776","journal-title":"J Clin Invest"},{"key":"1287_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colell","year":"2018","unstructured":"Colell\u00a0P, Ronzitti\u00a0G, Mingozzi\u00a0F (2018) Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev 8:87\u2013104","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1287_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke\u00a0ST, Baker\u00a0BF, Crooke\u00a0RM, Liang\u00a0XH (2021) Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20:427\u2013453","journal-title":"Nat Rev Drug Discov"},{"key":"1287_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/mt.2008.72","volume":"16","author":"SC Cunningham","year":"2008","unstructured":"Cunningham\u00a0SC, Dane\u00a0AP, Spinoulas\u00a0A, Alexander\u00a0IE (2008) Gene delivery to the juvenile mouse liver using AAV2\/8 vectors. Mol Ther 16:1081\u20131088","journal-title":"Mol Ther"},{"key":"1287_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras\u00a0BT, Masson\u00a0R, Mazurkiewicz-Be\u0142dzi\u0144ska\u00a0M et al (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N\u00a0Engl J Med 385:427\u2013435","journal-title":"N Engl J Med"},{"key":"1287_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41580-021-00389-z","volume":"22","author":"JJ Dowling","year":"2021","unstructured":"Dowling\u00a0JJ, Weihl\u00a0CC, Spencer\u00a0MJ (2021) Molecular and cellular basis of genetically inherited skeletal muscle disorders. Nat Rev Mol Cell Biol 22:713\u2013732","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1287_CR11","doi-asserted-by":"publisher","first-page":"e145994","DOI":"10.1172\/jci.insight.145994","volume":"6","author":"H Escobar","year":"2021","unstructured":"Escobar\u00a0H, Krause\u00a0A, Keiper\u00a0S et\u00a0al (2021) Base editing repairs an SGCA mutation in human primary muscle stem cells. JCI Insight 6:e145994","journal-title":"JCI Insight"},{"key":"1287_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore\u00a0JD, Gane\u00a0E, Taubel\u00a0J et al (2021) CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N\u00a0Engl J Med 385:493\u2013502","journal-title":"N Engl J Med"},{"key":"1287_CR13","doi-asserted-by":"publisher","first-page":"675897","DOI":"10.3389\/fimmu.2021.675897","volume":"12","author":"BA Hamilton","year":"2021","unstructured":"Hamilton\u00a0BA, Wright\u00a0JF (2021) Challenges posed by immune responses to AAV vectors: addressing root causes. Front Immunol 12:675897","journal-title":"Front Immunol"},{"key":"1287_CR14","doi-asserted-by":"publisher","first-page":"119142","DOI":"10.1016\/j.lfs.2021.119142","volume":"270","author":"L Huang","year":"2021","unstructured":"Huang\u00a0L, Wan\u00a0L, Wu\u00a0Y et al (2021) Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection. Life Sci 270:119142","journal-title":"Life Sci"},{"key":"1287_CR15","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/s41434-021-00222-4","volume":"28","author":"C Kupatt","year":"2021","unstructured":"Kupatt\u00a0C, Windisch\u00a0A, Moretti\u00a0A et\u00a0al (2021) Genome editing for Duchenne muscular dystrophy: a\u00a0glimpse of the future? Gene Ther 28:542\u2013548","journal-title":"Gene Ther"},{"key":"1287_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/nbt1153","volume":"23","author":"Y Lai","year":"2005","unstructured":"Lai\u00a0Y, Yue\u00a0Y, Liu\u00a0M et al (2005) Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 23:1435\u20131439","journal-title":"Nat Biotechnol"},{"key":"1287_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li\u00a0C, Samulski\u00a0RJ (2020) Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 21:255\u2013272","journal-title":"Nat Rev Genet"},{"key":"1287_CR18","doi-asserted-by":"publisher","first-page":"e143780","DOI":"10.1172\/JCI143780","volume":"131","author":"M Muhuri","year":"2021","unstructured":"Muhuri\u00a0M, Maeda\u00a0Y, Ma\u00a0H et\u00a0al (2021) Overcoming innate immune barriers that impede AAV gene therapy vectors. J\u00a0Clin Invest 131:e143780","journal-title":"J Clin Invest"},{"key":"1287_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.canlet.2021.02.011","volume":"505","author":"R Munagalaa","year":"2021","unstructured":"Munagalaa\u00a0R, Aqil\u00a0F, Jeyabalana\u00a0Y et al (2021) Exosome-mediated delivery of RNA and DNA for gene therapy. Cancer Lett 505:58\u201372","journal-title":"Cancer Lett"},{"key":"1287_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(21)00098-3","volume":"20","author":"YS Ng","year":"2021","unstructured":"Ng\u00a0YS, Bindoff\u00a0LA, Gorman\u00a0GS et\u00a0al (2021) Mitochondrial disease in adults: recent advances and future promise. Lancet Neurol 20:573\u2013584","journal-title":"Lancet Neurol"},{"key":"1287_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-1-4939-3753-0_19","volume":"1448","author":"S Ohno","year":"2016","unstructured":"Ohno\u00a0S, Kuroda\u00a0M (2016) Exosome-mediated targeted delivery of miRNAs. Methods Mol Biol 1448:261\u2013270","journal-title":"Methods Mol Biol"},{"key":"1287_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-018-0844-0","volume":"13","author":"M Pineda","year":"2018","unstructured":"Pineda\u00a0M, Walterfang\u00a0M, Patterson\u00a0MC (2018) Miglustat in Niemann-Pick disease type C patients: a\u00a0review. Orphanet J Rare Dis 13:140","journal-title":"Orphanet J Rare Dis"},{"key":"1287_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.omtm.2019.08.015","volume":"15","author":"S Pipe","year":"2019","unstructured":"Pipe\u00a0S, Leebeek\u00a0FWG, Ferreira\u00a0V, Sawyer\u00a0EK, Pasi\u00a0J (2019) Clinical considerations for capsid choice in the development of liver-targeted AAV-based gene transfer. Mol Ther Methods Clin Dev 15:170\u2013178","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1287_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00115-019-0724-4","volume":"90","author":"S-M Pulst","year":"2019","unstructured":"Pulst\u00a0S\u2011M (2019) Antisense Therapie Neurologischer Erkrankungen. Nervenarzt 90:781\u2013786","journal-title":"Nervenarzt"},{"key":"1287_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/molecules22040563","volume":"22","author":"V Sardone","year":"2017","unstructured":"Sardone\u00a0V, Zhou\u00a0H, Muntoni\u00a0F et al (2017) Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules 22:563","journal-title":"Molecules"},{"key":"1287_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","volume":"19","author":"E Tambuyzer","year":"2020","unstructured":"Tambuyzer\u00a0E, Vandendriessche\u00a0B, Austin\u00a0CP et\u00a0al (2020) Therapies for rare diseases: therapeutic modalities, progress, and challenges ahead. Nat Rev Drug Discov 19:93\u201311","journal-title":"Nat Rev Drug Discov"},{"key":"1287_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera\u00a0HC, Kuranda\u00a0K, Mingozzi\u00a0F (2020) AAV vector immunogenicity in humans: a\u00a0long journey to successful gene transfer. Mol Ther 28:723\u2013746","journal-title":"Mol. Ther."},{"key":"1287_CR28","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.3390\/molecules25122866","volume":"25","author":"A Wahane","year":"2020","unstructured":"Wahane\u00a0A, Waghmode\u00a0A, Kapphahn\u00a0A et al (2020) Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy. Molecules 25:2866","journal-title":"Molecules"},{"key":"1287_CR29","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/brain\/awab354","volume":"144","author":"L Zhang","year":"2021","unstructured":"Zhang\u00a0L, Wu\u00a0T, Shan\u00a0Y et al (2021) Therapeutic reversal of Huntington\u2019s disease by in vivo self-assembled siRNAs. Brain 144:3421\u20133435","journal-title":"Brain"},{"key":"1287_CR30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s00115-021-01251-5","volume":"93","author":"A Ziegler","year":"2022","unstructured":"Ziegler\u00a0A (2022) Pr\u00e4zisionsmedizin in der Kinderneurologie am Beispiel der neuen Therapien. Nervenarzt 93:122\u2013134","journal-title":"Nervenarzt"},{"issue":"1","key":"1287_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/jimd.12270","volume":"44","author":"HA Zittersteijn","year":"2021","unstructured":"Zittersteijn\u00a0HA, Gon\u00e7alves\u00a0MAFV, Hoeben\u00a0RC (2021) A primer to gene therapy: progress, prospects, and problems. J\u00a0Inherit Metab Dis 44(1):54\u201371","journal-title":"J Inherit Metab Dis"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-022-01287-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-022-01287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T14:05:35Z","timestamp":1655301935000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-022-01287-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s00115-022-01287-1","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"assertion":[{"value":"8 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Schoser gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}